Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-Current Deffered Revenue (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 87.9% to $1.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Sep 2025, down 87.9% year-over-year, with the annual reading at $6.0 million for FY2024, 81.45% down from the prior year.
  • Non-Current Deffered Revenue hit $1.5 million in Q3 2025 for Voyager Therapeutics, down from $2.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $78.9 million in Q1 2023 to a low of $1.5 million in Q3 2025.
  • Historically, Non-Current Deffered Revenue has averaged $20.7 million across 5 years, with a median of $12.2 million in 2024.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 833.51% in 2023 and later crashed 87.9% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $8.2 million in 2021, then dropped by 21.44% to $6.4 million in 2022, then soared by 401.69% to $32.4 million in 2023, then tumbled by 81.45% to $6.0 million in 2024, then plummeted by 75.5% to $1.5 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for VYGR at $1.5 million in Q3 2025, $2.6 million in Q2 2025, and $4.8 million in Q1 2025.